NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
← catalyst calendarNCT03589339 · readout in 253 d
Sponsored by Nanobiotix (industry) · NANO.PA — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
145estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-01-16 | actual | When the study began enrolling |
| Primary completion | 2027-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2018-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Radiotherapy
- Immunotherapy
- Microsatellite Instability-High Solid Malignant Tumour
- Metastasis From Malignant Tumor of Liver
- Squamous Cell Carcinoma of Head and Neck
- Metastasis From Malignant Tumor of Cervix
- Metastatic Renal Cell Carcinoma
- Metastasis From Malignant Melanoma of Skin (Disorder)
- Metastatic Triple-Negative Breast Carcinoma
- Metastatic NSCLC
- Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions
- Drug: NBTXR3
- Radiation: SABR — also filed as Stereotaxic Ablative Radiotherapy, Stereotaxic Body Radiation Therapy
- Drug: Nivolumab — also filed as Opdivo
- Drug: Pembrolizumab — also filed as Keytruda
Primary outcomes
what the primary-completion date above is the date OF[Dose Escalation Part]: Determination of the Recommended Dose
measured 24 Months
[Dose Expansion Part]: Safety Evaluation at RP2D
measured 24 Months
Publications
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NANO.PA's whole pipeline · Catalyst calendar · Every registered study · What changed